Slide

Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics

Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the publication of results from two clinical studies that evaluated the potential for drug-drug interactions of Imeglimin with two widely prescribed medications, metformin or sitagliptin.